These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 34469203)

  • 1. Evaluation of G protein bias and β-arrestin 2 signaling in opioid-induced respiratory depression.
    Bateman JT; Levitt ES
    Am J Physiol Cell Physiol; 2021 Oct; 321(4):C681-C683. PubMed ID: 34469203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ß-arrestin 2 germline knockout does not attenuate opioid respiratory depression.
    Bachmutsky I; Wei XP; Durand A; Yackle K
    Elife; 2021 May; 10():. PubMed ID: 34002697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biased Agonism: Lessons from Studies of Opioid Receptor Agonists.
    Kelly E; Conibear A; Henderson G
    Annu Rev Pharmacol Toxicol; 2023 Jan; 63():491-515. PubMed ID: 36170657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological and genetic manipulations at the µ-opioid receptor reveal arrestin-3 engagement limits analgesic tolerance and does not exacerbate respiratory depression in mice.
    He L; Gooding SW; Lewis E; Felth LC; Gaur A; Whistler JL
    Neuropsychopharmacology; 2021 Dec; 46(13):2241-2249. PubMed ID: 34257415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biased versus Partial Agonism in the Search for Safer Opioid Analgesics.
    Azevedo Neto J; Costanzini A; De Giorgio R; Lambert DG; Ruzza C; Calò G
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32854452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of β-arrestin recruitment by the μ-opioid G protein-coupled receptor.
    Mafi A; Kim SK; Goddard WA
    Proc Natl Acad Sci U S A; 2020 Jul; 117(28):16346-16355. PubMed ID: 32601232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphine-induced respiratory depression is independent of β-arrestin2 signalling.
    Kliewer A; Gillis A; Hill R; Schmiedel F; Bailey C; Kelly E; Henderson G; Christie MJ; Schulz S
    Br J Pharmacol; 2020 Jul; 177(13):2923-2931. PubMed ID: 32052419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of structurally novel G protein biased CB
    Ford BM; Franks LN; Tai S; Fantegrossi WE; Stahl EL; Berquist MD; Cabanlong CV; Wilson CD; Penthala NR; Crooks PA; Prather PL
    Pharmacol Res; 2017 Nov; 125(Pt B):161-177. PubMed ID: 28838808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Critical Assessment of G Protein-Biased Agonism at the μ-Opioid Receptor.
    Gillis A; Kliewer A; Kelly E; Henderson G; Christie MJ; Schulz S; Canals M
    Trends Pharmacol Sci; 2020 Dec; 41(12):947-959. PubMed ID: 33097283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Respiratory effects of low and high doses of fentanyl in control and β-arrestin 2-deficient mice.
    Haouzi P; McCann M; Tubbs N
    J Neurophysiol; 2021 Apr; 125(4):1396-1407. PubMed ID: 33656934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signaling diversity of mu- and delta- opioid receptor ligands: Re-evaluating the benefits of β-arrestin/G protein signaling bias.
    Pineyro G; Nagi K
    Cell Signal; 2021 Apr; 80():109906. PubMed ID: 33383156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An updated assessment of the translational promise of G-protein-biased kappa opioid receptor agonists to treat pain and other indications without debilitating adverse effects.
    French AR; van Rijn RM
    Pharmacol Res; 2022 Mar; 177():106091. PubMed ID: 35101565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of structure-activity relationships and biased agonism at the Mu opioid receptor of novel synthetic opioids using a novel, stable bio-assay platform.
    Vasudevan L; Vandeputte M; Deventer M; Wouters E; Cannaert A; Stove CP
    Biochem Pharmacol; 2020 Jul; 177():113910. PubMed ID: 32179045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. G protein signaling-biased mu opioid receptor agonists that produce sustained G protein activation are noncompetitive agonists.
    Stahl EL; Schmid CL; Acevedo-Canabal A; Read C; Grim TW; Kennedy NM; Bannister TD; Bohn LM
    Proc Natl Acad Sci U S A; 2021 Nov; 118(48):. PubMed ID: 34819362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and Structural Explorations of G-Protein Biased μ-Opioid Receptor Agonists.
    Li X; Guo Y; Li J; Yu Z; Cheng J; Ren F; Jia H; Zhang Y; Cui S; Zhang T; Shi W
    ChemMedChem; 2022 Dec; 17(24):e202200416. PubMed ID: 36210341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrinsic Efficacy of Opioid Ligands and Its Importance for Apparent Bias, Operational Analysis, and Therapeutic Window.
    Gillis A; Sreenivasan V; Christie MJ
    Mol Pharmacol; 2020 Oct; 98(4):410-424. PubMed ID: 32665252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The G protein-biased κ-opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo.
    White KL; Robinson JE; Zhu H; DiBerto JF; Polepally PR; Zjawiony JK; Nichols DE; Malanga CJ; Roth BL
    J Pharmacol Exp Ther; 2015 Jan; 352(1):98-109. PubMed ID: 25320048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Opioid Receptor Agonists with Reduced Morphine-like Side Effects.
    Zhu L; Cui Z; Zhu Q; Zha X; Xu Y
    Mini Rev Med Chem; 2018; 18(19):1603-1610. PubMed ID: 30009707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-analgesic effects of opioids: opioid-induced respiratory depression.
    Boom M; Niesters M; Sarton E; Aarts L; Smith TW; Dahan A
    Curr Pharm Des; 2012; 18(37):5994-6004. PubMed ID: 22747535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bias Factor and Therapeutic Window Correlate to Predict Safer Opioid Analgesics.
    Schmid CL; Kennedy NM; Ross NC; Lovell KM; Yue Z; Morgenweck J; Cameron MD; Bannister TD; Bohn LM
    Cell; 2017 Nov; 171(5):1165-1175.e13. PubMed ID: 29149605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.